The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
 
Brandon Arvin Virgil Mahal
No Relationships to Disclose
 
Yu-Wei Chen
No Relationships to Disclose
 
Vinayak Muralidhar
No Relationships to Disclose
 
Amandeep R. Mahal
No Relationships to Disclose
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Karen E. Hoffman
No Relationships to Disclose
 
Jim C. Hu
Speakers' Bureau - Genomic Health; Intuitive Surgical
Travel, Accommodations, Expenses - Intuitive Surgical
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen Biotech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Clair Beard
No Relationships to Disclose
 
Neil E. Martin
No Relationships to Disclose
 
Felix Yi-Chung Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Simon P. Kim
No Relationships to Disclose
 
James B. Yu
Research Funding - 21st Century Oncology (Inst)
 
Quoc-Dien Trinh
No Relationships to Disclose
 
Paul L. Nguyen
Consulting or Advisory Role - Ferring; GenomeDx; Medivation
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Wife has a patent on volatile diagnostics of infections (I)